- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02307409
Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis
This study attempts to clarify the pathophysiology of haemostasis and haematopoiesis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in ACLF (Acute on Chronic Liver Failure) patients in particular, to correctly identify the type and optimal quantity of blood product requirement in at risk patients.
Thromboelastography (TEG) /Sonoclot have been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with ACLF (Acute on Chronic Liver Failure) without evidence of sepsis on admission will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and haematopoietic cellular responses will be assessed. Thus the effect of sepsis on the progression and outcome of patients with ACLF (Acute on Chronic Liver Failure) will be studied.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Institute of Liver & Biliary Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-65 years
- ACLF (Acute on Chronic Liver Failure), as diagnosed by APASL (Asian Pacific association of Study of Liver Disease) criteria mentioned above.
Exclusion Criteria:
- Patients with evidence of sepsis at presentation.
- Current therapy: Recent blood or blood component transfusion in the last 2 days.
- HIV positive/ AIDS patients
- Patients requiring anti platelet therapy,
- Renal insufficiency requiring dialysis
- Active malignancy within the last 5 years
- Patient with other neurological disease and metabolic disorders, unbalanced heart failure and/or respiratory failure or end-stage renal disease
- Administration of anticoagulants, antifibrinolytics,
- Not willing to participate in the study
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Decompensated Chronic Liver Disease
Decompensated Chronic Liver Disease patients will be enrol
|
The Sonoclot/TEG test will be done at the study time points.
Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
|
|
Healthy Controls
Healthy Controls will be enrol
|
The Sonoclot/TEG test will be done at the study time points.
Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence and severity of coagulation profile derangement and haematopoietic responses, by sonoclot/ TEG, coagulation and hematological parameters, in acute- on-chronic liver failure with and without systemic inflammatory response.
Time Frame: 0 day, 3 day & 7 day after admission.
|
0 day, 3 day & 7 day after admission.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Utility of sonoclot/ TEG in predicting blood product utilization.
Time Frame: 0 day, 3 day & 7 day after admission.
|
Reporting of blood product usage in 7 days of admission as per TEG R time, K time, Maximum amplitude of curve, angle, lysis at 30%.
|
0 day, 3 day & 7 day after admission.
|
|
Sonoclot/TEG result indicating hypocoagulability correlates with the patient's tendency to bleed in ACLF.
Time Frame: 0 day, 3 day & 7 day after admission.
|
Reporting of number and site of bleed- skin, mucosa, urine, GI tract, CNS etc.
|
0 day, 3 day & 7 day after admission.
|
|
Changes in baseline coagulation profile can predict development of sepsis in patients of ACLF.
Time Frame: 0 day, 3 day & 7 day after admission.
|
Correlation of PT/INR with TEG parameters and positive blood or urine culture.
|
0 day, 3 day & 7 day after admission.
|
|
Coagulation dysfunction (prothrombotic and anticoagulant tendencies) in patients with ACLF with or without evidence of sepsis.
Time Frame: 0 day, 3 day & 7 day after admission.
|
0 day, 3 day & 7 day after admission.
|
|
|
Effect of sepsis on the haematopoietic response of patients with Acute on Chronic Liver Failure.
Time Frame: 0 day, 3 day & 7 day after admission.
|
Measurement of reticulocyte count, and peripheral amear- presence of toxic granules.
|
0 day, 3 day & 7 day after admission.
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Premkumar M, Bihari C, Saxena P, Devurgowda DR, Vyas T, Mirza R, Jain P, Kumar G, Bhatia P, Baweja S, Choudhury A, Sarin SK. Heparin-like Effect Associated With Risk of Bleeding, Sepsis, and Death in Patients With Severe Alcohol-Associated Hepatitis. Clin Gastroenterol Hepatol. 2020 Feb;18(2):486-495.e3. doi: 10.1016/j.cgh.2019.04.057. Epub 2019 May 8.
- Premkumar M, Saxena P, Rangegowda D, Baweja S, Mirza R, Jain P, Bhatia P, Kumar G, Bihari C, Kalal C, Vyas T, Choudhury A, Sarin SK. Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: An observational cohort study. Liver Int. 2019 Apr;39(4):694-704. doi: 10.1111/liv.14034. Epub 2019 Feb 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILBS-SIRS-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute on Chronic Liver Failure
-
GenfitCompletedAcute-on-Chronic Liver FailureUnited States
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAcute on Chronic Liver Failure (ACLF)Italy
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruiting
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Third Affiliated Hospital, Sun Yat-Sen UniversityActive, not recruitingAcute-on-Chronic Liver Failure (ACLF)China
-
Pere GinesClinica Universidad de Navarra, Universidad de NavarraTerminatedAllogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure (Liveradvance)Acute on Chronic Hepatic FailureSpain
Clinical Trials on Sonoclot/TEG test
-
The University of Texas Health Science Center,...CompletedIschemic Stroke | Brain HemorrhageUnited States
-
Triemli HospitalUniversity of ZurichCompletedCoagulation Disorder, BloodSwitzerland
-
Assiut UniversityNot yet recruitingStudy of Hemostatic Profile in Traumatic Patients
-
Francesco EgroNot yet recruiting
-
Washington University School of MedicineOrthopedic Research and Education FoundationTerminatedNeuromuscular ScoliosisUnited States
-
Assiut UniversityNot yet recruiting
-
Postgraduate Institute of Medical Education and...UnknownCovid19 | Hypercoagulable States NecIndia
-
University of Colorado, DenverHaemonetics CorporationRecruitingColorectal Cancer | Esophageal Cancer | Lung Adenocarcinoma | Pancreas Cancer | Liver Cancer | Biliary Cancer | ControlUnited States
-
Hvidovre University HospitalRigshospitalet, DenmarkCompletedBlood Loss | Hip FractureDenmark
-
Brigham and Women's HospitalUnknownMesothelioma | CoagulopathyUnited States